307 related articles for article (PubMed ID: 33155179)
1. Single domain antibody-based vectors in the delivery of biologics across the blood-brain barrier: a review.
Gao Y; Zhu J; Lu H
Drug Deliv Transl Res; 2021 Oct; 11(5):1818-1828. PubMed ID: 33155179
[TBL] [Abstract][Full Text] [Related]
2. Strategies to identify, engineer, and validate antibodies targeting blood-brain barrier receptor-mediated transcytosis systems for CNS drug delivery.
Choi ES; Shusta EV
Expert Opin Drug Deliv; 2023; 20(12):1789-1800. PubMed ID: 38007619
[TBL] [Abstract][Full Text] [Related]
3. Emerging Technologies for Delivery of Biotherapeutics and Gene Therapy Across the Blood-Brain Barrier.
Stanimirovic DB; Sandhu JK; Costain WJ
BioDrugs; 2018 Dec; 32(6):547-559. PubMed ID: 30306341
[TBL] [Abstract][Full Text] [Related]
4. Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier.
Lajoie JM; Shusta EV
Annu Rev Pharmacol Toxicol; 2015; 55():613-31. PubMed ID: 25340933
[TBL] [Abstract][Full Text] [Related]
5. Brain uptake of multivalent and multi-specific DVD-Ig proteins after systemic administration.
Karaoglu Hanzatian D; Schwartz A; Gizatullin F; Erickson J; Deng K; Villanueva R; Stedman C; Harris C; Ghayur T; Goodearl A
MAbs; 2018 Jul; 10(5):765-777. PubMed ID: 29771629
[TBL] [Abstract][Full Text] [Related]
6. A Perfused In Vitro Human iPSC-Derived Blood-Brain Barrier Faithfully Mimics Transferrin Receptor-Mediated Transcytosis of Therapeutic Antibodies.
Burgio F; Gaiser C; Brady K; Gatta V; Class R; Schrage R; Suter-Dick L
Cell Mol Neurobiol; 2023 Nov; 43(8):4173-4187. PubMed ID: 37698826
[TBL] [Abstract][Full Text] [Related]
7. Transportation of Single-Domain Antibodies through the Blood-Brain Barrier.
Ruiz-López E; Schuhmacher AJ
Biomolecules; 2021 Jul; 11(8):. PubMed ID: 34439797
[TBL] [Abstract][Full Text] [Related]
8. Smart Strategies for Therapeutic Agent Delivery into Brain across the Blood-Brain Barrier Using Receptor-Mediated Transcytosis.
Tashima T
Chem Pharm Bull (Tokyo); 2020; 68(4):316-325. PubMed ID: 32238649
[TBL] [Abstract][Full Text] [Related]
9. Brain Delivery of IGF1R5, a Single-Domain Antibody Targeting Insulin-like Growth Factor-1 Receptor.
Yogi A; Hussack G; van Faassen H; Haqqani AS; Delaney CE; Brunette E; Sandhu JK; Hewitt M; Sulea T; Kemmerich K; Stanimirovic DB
Pharmaceutics; 2022 Jul; 14(7):. PubMed ID: 35890347
[TBL] [Abstract][Full Text] [Related]
10. Antibody screening using a human iPSC-based blood-brain barrier model identifies antibodies that accumulate in the CNS.
Georgieva JV; Goulatis LI; Stutz CC; Canfield SG; Song HW; Gastfriend BD; Shusta EV
FASEB J; 2020 Sep; 34(9):12549-12564. PubMed ID: 32960493
[TBL] [Abstract][Full Text] [Related]
11. Application of In vitro transcytosis models to brain targeted biologics.
Deng K; Lu Y; Finnema SJ; Vangjeli K; Huang J; Huang L; Goodearl A
PLoS One; 2023; 18(8):e0289970. PubMed ID: 37611031
[TBL] [Abstract][Full Text] [Related]
12. Standardized Preclinical
Morrison JI; Petrovic A; Metzendorf NG; Rofo F; Yilmaz CU; Stenler S; Laudon H; Hultqvist G
Mol Pharm; 2023 Mar; 20(3):1564-1576. PubMed ID: 36808999
[TBL] [Abstract][Full Text] [Related]
13. Use of LDL receptor-targeting peptide vectors for
Molino Y; David M; Varini K; Jabès F; Gaudin N; Fortoul A; Bakloul K; Masse M; Bernard A; Drobecq L; Lécorché P; Temsamani J; Jacquot G; Khrestchatisky M
FASEB J; 2017 May; 31(5):1807-1827. PubMed ID: 28108572
[TBL] [Abstract][Full Text] [Related]
14. A novel platform for engineering blood-brain barrier-crossing bispecific biologics.
Farrington GK; Caram-Salas N; Haqqani AS; Brunette E; Eldredge J; Pepinsky B; Antognetti G; Baumann E; Ding W; Garber E; Jiang S; Delaney C; Boileau E; Sisk WP; Stanimirovic DB
FASEB J; 2014 Nov; 28(11):4764-78. PubMed ID: 25070367
[TBL] [Abstract][Full Text] [Related]
15. Brain penetration, target engagement, and disposition of the blood-brain barrier-crossing bispecific antibody antagonist of metabotropic glutamate receptor type 1.
Webster CI; Caram-Salas N; Haqqani AS; Thom G; Brown L; Rennie K; Yogi A; Costain W; Brunette E; Stanimirovic DB
FASEB J; 2016 May; 30(5):1927-40. PubMed ID: 26839377
[TBL] [Abstract][Full Text] [Related]
16. Isolation of blood-brain barrier-crossing antibodies from a phage display library by competitive elution and their ability to penetrate the central nervous system.
Thom G; Hatcher J; Hearn A; Paterson J; Rodrigo N; Beljean A; Gurrell I; Webster C
MAbs; 2018; 10(2):304-314. PubMed ID: 29182455
[TBL] [Abstract][Full Text] [Related]
17. Treatment of Parkinson's disease with biologics that penetrate the blood-brain barrier via receptor-mediated transport.
Pardridge WM
Front Aging Neurosci; 2023; 15():1276376. PubMed ID: 38035276
[TBL] [Abstract][Full Text] [Related]
18. Targeting blood-brain-barrier transcytosis - perspectives for drug delivery.
Mäger I; Meyer AH; Li J; Lenter M; Hildebrandt T; Leparc G; Wood MJA
Neuropharmacology; 2017 Jul; 120():4-7. PubMed ID: 27561970
[TBL] [Abstract][Full Text] [Related]
19. Delivery of Biologics Across the Blood-Brain Barrier with Molecular Trojan Horse Technology.
Pardridge WM
BioDrugs; 2017 Dec; 31(6):503-519. PubMed ID: 29067674
[TBL] [Abstract][Full Text] [Related]
20. Transcellular brain drug delivery: A review on recent advancements.
Azarmi M; Maleki H; Nikkam N; Malekinejad H
Int J Pharm; 2020 Aug; 586():119582. PubMed ID: 32599130
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
